Explore our resources by research/diagnostic specialty or content type

For laboratories with a compatible clinical chemistry analyzer, on-boarding of the calprotectin immunoturbidimetric assay is simple.

• No capital purchase or additional instrument space required
• Minimal assay training and hands-on time
• ALPCO assistance with validation kits and well-characterized samples

With clinical sensitivity of 91% and clinical specificity of 93%, the ALPCO calprotectin immunoturbidimetric assay offers the efficiency of automation without sacrificing clinical performance. Internal reference controls and a well-characterized sample panel ensure consistency (inter-lot CV of only 4%) over time.

Test results from outside laboratories can sometimes take up to 5 days. Random access testing enables laboratories to offer affordable same-day results. On-site testing eliminates the shipping process and maintains remnant samples on-site. Clinicians can schedule follow-up colonoscopy for the patients that need it most and quickly start IBS patients on the right treatment path.

The cost per test to run the ALPCO Calprotectin Turbidimetric Assay is typically far less than the send-out price. With calprotectin testing expected to increase at a CAGR of 6%, in-house calprotectin testing can be a source of continued revenue growth. An ALPCO specialist can work with you to calculate the cost savings and revenue potential associated with the switch to in-house testing for your institution.

The Calprotectin Immunoturbidimetric Assay combines the clinical sensitivity and specificity clinicians expect with the efficiency and reproducibility that today’s laboratories require.

The Calprotectin Immunoturbidimetric Assay is an in vitro diagnostic particle-enhanced immunoassay for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation.

The assay is intended for in vitro diagnostic use as an aid in the diagnosis of inflammatory bowel disease (IBD) and as an aid in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other clinical and laboratory findings.

CE-marked. 510(k) cleared.

• Clinical Sensitivity of 91%
• Clinical Specificity of 93%
• Inter-lot CV of only 4%

• No capital purchase required
• High throughput
• Minimal hands-on time
• Ease-of-Use
• Consistency of automated processing

• Simple workflow
• Consistent sample processing
• No manual weighing
• Several compatible GI assays

* Specifications based on Beckman AU680 Analyzer after first hour
** Automatically metered by FDA-cleared extraction device